Otsuka Pharmaceutical

Last updated

Otsuka Pharmaceutical Co., Ltd.
Native name
大塚製薬株式会社
Romanized name
Ōtsuka Seiyaku Kabushiki-gaisha
Type Public KK
TYO: 4578
TOPIX 100 Component
Industry Pharmaceutical
Founded1921 (Originally founded), 1964 (Current corporation)
FounderBusaburo Otsuka
Headquarters,
Number of locations
69
Area served
Worldwide
Key people
Tatsuo Higuchi (President)
Revenue¥ 531.2 billion (2017)
¥ 57.0 billion (2017)
Owner Nomura Trust and Banking investment trusts (11.43%)
and investment trusts managed by other banks
Number of employees
5,634 (2017)
Parent Otsuka Holdings Co. Ltd
Website otsuka.com
Products of Otsuka Pharmaceutical Products of Otsuka Pharmaceutical.jpg
Products of Otsuka Pharmaceutical

Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社, Ōtsuka Seiyaku Kabushiki-gaisha) (TYO : 4578), abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.

Contents

History

OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company. [1] The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time. [1]

Otsuka Pharmaceutical Co. LTD Holdings

In 1955, the company started a football club called "Otsuka Pharmaceutical SC." In 2005 the name changed to Tokushima Vortis. The club is based in Naruto. [2]

In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of CG Roxane. [3]

In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready ADHD drug centanafadine (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary. [4]

In July 2017, they bought Daiya [5]

In July 2018, Otsuka agreed to acquire Visterra for $430 million cash. [6]

Products

Otsuka Holdings Co. Ltd. Holdings

In 1990, Otsuka Holdings Co. Ltd. acquired Crystal Geyser Water Company. [9]

In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology". [10] This decision necessitated a revision in the terms of an agreement with UCB to end collaboration on immunology products while continuing collaboration in the CNS area. [11]

In September 2013, Otsuka Holdings it acquired Astex Pharmaceuticals for close to $900 million. [12]

In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion. [13]

In July 2018, Otsuka Holdings acquired renal-focused ReCor Medical, Inc. [14]

Related Research Articles

Takeda Pharmaceutical Company Pharmaceutical company in Asia

The Takeda Pharmaceutical Company Limited[takeꜜda jakɯçiŋ koꜜːɡʲoː] is a Japanese multinational pharmaceutical and biopharmaceutical company. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US $19.299 billion in revenue during the 2018 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and President of Takeda.

Aripiprazole Atypical Antipsychotic

Aripiprazole, sold under the brand name Abilify among others, is an atypical antipsychotic. It is primarily used in the treatment of schizophrenia and bipolar disorder. Other uses include as an add-on treatment in major depressive disorder, tic disorders and irritability associated with autism. It is taken by mouth or injection into a muscle. A Cochrane review found evidence of effectiveness in treating schizophrenia.

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It is perhaps best known for its involvement in developing the Oxford-AstraZeneca COVID-19 vaccine.

Fasoracetam Chemical compound

Fasoracetam is a research chemical of the racetam family. It is a putative nootropic that failed to show sufficient efficacy in clinical trials for vascular dementia. It is currently being studied for its potential use for attention deficit hyperactivity disorder.

Tokushima Vortis Japanese football club

Tokushima Vortis is a Japanese professional football club, currently playing in the J1 League. The team is located in Tokushima, Tokushima Prefecture. Their home stadium is Naruto Otsuka Sports Park Pocari Sweat Stadium, in Naruto, Tokushima.

Astex Pharmaceuticals ("Astex") is a biotechnology company focused on the discovery and development of drugs in oncology and diseases of the central nervous system. Astex was founded in 1999 by Sir Tom Blundell, Chris Abell & Harren Jhoti, and is located in Cambridge, England.

UCB (company) Biopharmaceutical company

UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with a revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's, and Crohn's diseases. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders, inflammatory disorders, and oncology.

C.H. Boehringer Sohn AG & Ko. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.

Celltech

Celltech Group plc was a leading British-based biotechnology business based in Slough. It was listed on the London Stock Exchange and was a constituent of the FTSE 100 Index.

Astellas Pharma Japanese pharmaceutical company

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.. On February 5, 2020, the company announced management changes effective from April 1, 2020.

Teva Pharmaceuticals Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd., also known as Teva Pharmaceuticals, is a global pharmaceutical company with headquarters in Petah Tikva, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. In 2020, Teva Pharmaceuticals was the second largest generic drug manufacturer and the eighteenth largest pharmaceutical company in the world.

Daiichi Sankyo Japanese pharmaceutical company

Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.

Harren Jhoti

Harren Jhoti is a structural biologist whose main interest has been rational drug design and discovery. He is President & Chief Executive Officer (CEO) of biotechnology company Astex Pharmaceuticals ("Astex") which is located in Cambridge, United Kingdom (UK).

Taiho Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company, subsidiary of Otsuka Holdings. The company focuses on developing cancer treatments. Taiho is headquartered in Tokyo, Japan. Taiho is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology.

Ōtsuka is a Japanese surname.

Lupin Limited Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai, Maharashtra, India. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

Brexpiprazole Dopamine D2 receptor partial agonist and "serotonin–dopamine activity modulator"

Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic. It is a dopamine D2 receptor partial agonist and has been described as a "serotonin–dopamine activity modulator" (SDAM). The drug was approved by the U.S. Food and Drug Administration (FDA) on July 10, 2015, for the treatment of schizophrenia, and as an adjunctive treatment for depression. It has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

David Charles Rees British chemist

David Charles Rees CChem, FRSC is a chemist whose main research interest is discovering new medicines. He is Chief Scientific Officer at Astex Pharmaceuticals Cambridge UK, a biotechnology company focussed on Fragment Based Drug Discovery. In 2003 David was hired by Astex to lead the chemistry team, and became Chief Scientific Officer in 2017. Three anti-cancer agents were created in research involving David: ribociclib and erdafitinib and the anaesthetic agent sugammadex which had global sales of US$917 million in 2018. David was President of the Organic Division from 2010 to 2013 of the Royal Society of Chemistry and was later elected as a Trustee of the RSC (2015-2019). He is a Director of Ashanti Development, a charity that promotes clean water and sanitation in Ghana.

References

  1. 1 2 Fujita, Junko; Slodkowski, Antoni (December 16, 2010), Nathan Layne (ed.), Otsuka up 5 pct in Tokyo debut after $2.4 bln IPO-UPDATE 1 (Reuters news), Forexyard, forexyard.com, archived from the original on March 4, 2012, retrieved January 15, 2012
  2. "Tokushima Vortis" . Retrieved October 30, 2020.
  3. "Otsuka Pharmaceutical Co., Ltd. invests in French leading mineral water company, ALMA S.A." otsuka.co.jp. May 28, 2008. Retrieved October 30, 2020.
  4. "Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN". GEN. Retrieved 23 April 2018.
  5. "Plant-based food firm Daiya bought for $325.97M by pharma company Otsuka". Food Dive.
  6. "Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms". July 11, 2018.
  7. "Aripiprazole". AdisInsight. Retrieved 4 June 2017.
  8. Behere, Prakash B.; Das, Anweshak; Behere, Aniruddh P. (2018). Clinical Psychopharmacology: An Update. Springer. p. 66. ISBN   9789811320927.
  9. Otsuka.com Library, Otsuka Pharmaceutical. Retrieved September 21, 2019.
  10. Otsuka Pharmaceutical Co., Ltd. and UCB Group (UCBJF.PK) End Cimzia Collaboration, to Focus on CNS Disorders Instead, BioSpace, January 13, 2012, archived from the original on March 3, 2016, retrieved January 15, 2012
  11. UCB and Otsuka to focus collaboration on CNS disorders, Zenopa, January 13, 2012, zenopa.com, retrieved January 15, 2012
  12. Tim Kelly (5 September 2013). "Japan's Otsuka to buy cancer drug maker Astex Pharma". Reuters.
  13. Soble, Jonathan. "Otsuka of Japan to Buy Avanir Pharmaceuticals for $3.5 Billion". nytimes.com. Retrieved 23 April 2018.
  14. "Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement". BioSpace.